Leukemia, Myeloid, Chronic-Phase Clinical Trial
Official title:
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
The main objective of this study is to evaluate the existence of a relationship between the presence of certain abl polymorphisms (or haplotypes) upon CML diagnosis and the occurrence of primary resistance to the treatment of CML by imatinib.
The first secondary objective of this study is to identify, in patients not responding to
treatment, possible changes in the polymorphisms of interest during the course of the
disease, reclassifying such polymorphisms as mutations.
The second secondary objective is to compare the control patients in terms of polymorphism
frequency on the nonpathological abl fraction.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01725204 -
Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia
|
Phase 2 | |
| Completed |
NCT00103701 -
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Completed |
NCT01856283 -
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
|
Phase 2 | |
| Completed |
NCT00048672 -
Therapy of Early Chronic Phase CML With Gleevec
|
Phase 2 | |
| Recruiting |
NCT02767063 -
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)
|
Phase 1/Phase 2 | |
| Terminated |
NCT01827930 -
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
|
Phase 3 | |
| Terminated |
NCT01488253 -
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
|
Phase 2 | |
| Completed |
NCT02888964 -
Pioglityazone and Imatinib for CML Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03239886 -
Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log
|
N/A | |
| Terminated |
NCT03807479 -
Study in Patients With Chronic Leukemia
|
Phase 2 |